Incyte Announces Positive Results from a Phase 2 Study of ...

Immunovaccine And Incyte Expand Clinical Collaboration ...

The Companies plan to add a Phase 2 component to their ongoing Phase 1b combination study evaluating the safety and efficacy of Immunovaccine's ...

FDA Approves Ruxolitinib for Chronic GVHD - OncLive

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia. ... announces-positive-pivotal ...

Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta ...

The CHMP opinion is based on data the Phase 2 GEOMETRY mono-1 study that demonstrated positive overall response rates (ORR) among adult ...

Incyte Announces Positive Updated Results From Phase 2 Trial Of ...

In patients harboring FGFR2 fusions or rearrangements (Cohort A), pemigatinib monotherapy resulted in an overall response rate (ORR) of 36 ...

Incyte's Povorcitinib Shows Positive Results in Managing Extensive ...

Incyte announced new data from a phase 2b clinical trial, which evaluated the efficacy and safety of povorcitinib (INCB54707) in adults with ...

Topline results from two phase III clinical studies evaluating ...

Incyte announces positive topline results from two Phase III clinical studies evaluating retifanlimab (Zynyz), a humanized monoclonal ...

Oral Povorcitinib for Extensive Nonsegmental Vitiligo Yields Positive ...

The new 52-week data from EADV was announced by Incyte, and had resulted from a phase 2b clinical trial assessing the safety and the ...

Incyte Corporation Inks Deal to Acquire Escient Pharmaceuticals for ...

Currently in a Phase II study for chronic spontaneous urticaria ... ESCIENT PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 1 STUDY ...

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab ...

SG has notable efficacy compared with historical controls in pretreated mUC that has progressed on both prior PLT regimens and CPI. The results from this study ...

Randomized Phase 2 Clinical Trial of Olaratumab in Combination ...

The aim of the ANNOUNCE 2 trial was to explore the addition of olaratumab (O) to gemcitabine (G) and docetaxel (D) for advanced STS. Patients ...

Incyte Announces Positive CHMP Opinion for Pemigatinib for the ...

The FIGHT (FIbroblast Growth factor receptor in oncology and Hematology Trials) clinical trial program includes ongoing Phase 2 and 3 studies investigating ...

Major Events in the Pharmaceutical Industry! (April 2020) - LinkedIn

1. Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 2.

Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 ...

The MAHOGANY study is based on results from an ongoing Phase 2 study of margetuximab plus pembrolizumab, an anti-PD-1 monoclonal antibody ...

Incyte Stock News (INCY) - Page 17 - Public.com

News for Incyte Stock (INCY) · Incyte (INCY) Announces Positive Results From Vitiligo Study · Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing ...

Global New Drug Research and Development Progress Weekly ...

On June 24th, Roche announced that the NMPA has officially approved an update to the prescribing information for its hematologic cancer drug, ...

Incyte Announces Positive 52-Week Results From a Randomized ...

Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo; Track. Incyte ...

Lilly and Incyte Announce Positive Top-Line Results from the North ...

"Today's results, together with the previously reported positive top-line results from our Phase 3 trials, reinforce our commitment to pursue ...

Lilly and Incyte announce positive top-line results from Phase 3 trial ...

Lilly and Incyte announce positive top-line results from Phase 3 trial of baricitinib in moderate to severe rheumatoid arthritis · Related topics.

Incyte Announces Positive Topline Results from Pivotal Study of ...

Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®) or placebo in combination with lenalidomide and rituximab met its primary ...

Phase 3 RUX Update - Vitiligo Research, new cream to treat vitiligo

In fact, the Phase 3 results looked very similar to the Phase 2 results (a very good sign that the treatment works as hoped), and there were no ...